Recent Articles By The Author
The next six months can't be worse than the first six, can they?
I expect biotech M&A activity to pick up in the back half of 2022.
There has been a lack of overbuilding in the housing market and inventories remain low.
Here's how to aim for this gunmaker once more with a covered-call play.
This particular biotech company just saw its stock whacked but still holds a lot of promise.
There are too many events that need to happen first before a solid bottom is formed.